Is Novavax Stock A Buy Or Sell As It Approaches A Potential U.S. Filing?

1 year ago 197
PR Distribution

Novavax banal was nether unit successful January contempt winning conditional authorization for its Covid vaccine successful Europe and finalizing the information needed for a U.S. submission.


In precocious December, Novavax (NVAX) submitted chemistry, manufacturing and controls information for its Covid vaccine to the Food and Drug Administration. The institution said it expects to inquire for exigency authorization of its Covid regimen successful a month.

It's the archetypal protein-based Covid changeable to summation authorization successful Europe and volition connection an alternate to radical hesitant to person messenger RNA, oregon mRNA, vaccines from Pfizer (PFE) and Moderna (MRNA).

But Novavax shares toppled amid the omicron variant's spread. Recently, the Centers for Disease Control and Prevention said the highly transmissible variant is starring delta successful the U.S. Omicron's spike macromolecule contains mutations that undo the effectiveness of vaccines from Pfizer and Moderna — though some accidental booster shots make precocious levels of antibodies.

Novavax has besides said its two-dose vaccine produces omicron-blocking antibodies. A 3rd dose generates accrued immune responses, the institution says. The institution began its Phase 3 booster changeable survey successful precocious December.

But NVAX banal was beneath its 50-day moving average connected Jan. 13, according to Shares besides fell aft a study suggested the company's Covid vaccine is facing manufacturing issues successful the U.S. Unnamed sources said the changeable is lagging purity standards successful the U.S. Contaminants oregon unnecessary substances could undermine the vaccine's effectiveness oregon present broadside effects.

So, is it clip to bargain oregon merchantability NVAX stock?

Fundamental Analysis Of NVAX Stock

Novavax isn't measuring up to CAN SLIM guidelines for successfully trading maturation stocks.

The institution has reported years of yearly losses, a inclination expected to proceed successful 2021. While this is simply a communal trait for pre-commercial biotech companies — which are usually investing successful probe and improvement — it's not desirable from a CAN SLIM perspective.

For 2021, NVAX banal analysts polled by FactSet expect the institution to suffer $12.31 per share. That could plaything to a $26.58 summation adjacent year, assuming the institution broadly launches its Covid vaccine. Analysts besides expect $1.38 cardinal successful 2021 gross to turn to $4.62 cardinal successful 2022.

In the 3rd quarter, Novavax reported a per-share nonaccomplishment of $4.31 and $179 cardinal successful sales. Losses per stock deepened, but gross roseate 14%. And some measures lagged expectations. In the 4th quarter, analysts expect Novavax to suffer 40 cents per stock connected $454 cardinal successful sales.

Savvy investors should look for companies reporting caller quarterly revenue and net growth of astatine slightest 20%-25%. Novavax isn't expected to crook astir a nett this year. Stocks with this benignant of grounds are much speculative and transportation higher risks for investors.

In the 3rd quarter, Novavax's gross was wholly tied to improvement agreements. It lone conscionable gained the archetypal authorizations for its Covid vaccine successful November.

Novavax's Planned Coronavirus Vaccine

Novavax's Covid vaccine is present disposable successful respective countries including India, Indonesia and South Korea. Novavax besides has authorizations successful Europe and from the World Health Organization. The institution has besides filed for authorization successful a fig of countries.

In the Phase 3 U.K. study, Novavax said its Covid vaccine was 89.7% effective. Another survey successful the U.S. and Mexico recovered the vaccine to beryllium much than 90.4% effective. The institution besides says it could statesman making an omicron-specific vaccine wrong a fewer weeks.

NVAX banal has a Composite Rating of 11 retired of a best-possible 99. The Composite Rating is simply a 1-99 measurement of a stock's method and cardinal maturation metrics. On this measure, NVAX banal ranks successful the bottommost one-quarter of each stocks.

Shares besides person a debased EPS Rating of 6. The EPS Rating is simply a measurement of profitability and, connected that bar, NVAX banal is weak. (Keep tabs connected IBD Digital for much connected banal ratings.)

Mutual funds clasp a bully chunk of the biotech stock. As of December, 826 funds owned 30% of Novavax stock. Institutional enactment is simply a bully sign.

What Does History Say About Novavax Stock?

Novavax uses insect cells to make molecules for vaccine improvement astatine a faster gait than the humanities process, which relies connected chickenhearted eggs. Although authorities agencies person seen committedness successful that technology, NVAX banal is plagued by immoderate high-profile disappointments.

In 2011, the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority gave Novavax $179 cardinal to make a flu vaccine. Nine years later, that flu vaccine succeeded successful the final-phase test. The adjacent day, Novavax banal popped 4%.

But its vaccine to dainty respiratory syncytial microorganism hasn't had the aforesaid luck. The biotech institution received $89 cardinal from the Bill & Melinda Gates Foundation successful 2015 to make the vaccine. A twelvemonth later, the vaccine didn't conscionable its superior oregon secondary goals successful older adults and Novavax laid off astir a 3rd of its staff.

Novavax banal ended 2016 with a spectacular downfall. Shares plummeted 85% that year.

In 2019, the vaccine failed successful large women and Novavax announced a reverse banal split to debar delisting from the Nasdaq. The biotech institution besides sold immoderate manufacturing facilities to Catalent (CTLT) to rise $18 cardinal successful cash.

That year, NVAX banal plunged 89%.

Novavax banal investors proceed watching for updates connected the company's Covid vaccine. The institution has received backing from the Coalition for Epidemic Preparedness, a planetary confederation to halt epidemics. The Gates Foundation and the U.S. authorities besides gave Novavax wealth to assistance velocity its improvement of a Covid vaccine.

Technical Analysis Of NVAX Stock

Covid vaccine quality has spiked Novavax stock.

Novavax banal has a Relative Strength Rating of 19. The RS Rating pits each stocks, careless of manufacture group, against 1 different successful presumption of 12-month terms performance. On this measure, NVAX banal outranks 19% of each stocks. Leading stocks thin to person RS Ratings of astatine slightest 80.

NVAX banal isn't presently forming a definitive illustration pattern, shows. On Jan. 13, shares were good beneath their 200-day moving average.

So, Is Novavax Stock A Buy Or Sell?

As of Jan. 13, NVAX banal wasn't showing immoderate entries to buy, and trading beneath its 50-day enactment remains a bearish sign. Also, shares aren't presently forming a caller illustration pattern. Investors are encouraged to bargain a banal erstwhile it crosses a bargain constituent and is wrong its 5% pursuit zone.

(Keep an oculus connected Stocks Near A Buy Zone.) 

On a cardinal level, NVAX banal is plagued by years of losses and its gross remains low. That could alteration if Novavax gains further authorizations for Covid vaccine. Still, Novavax banal remains a speculative investment.

It volition beryllium important to ticker Novavax's efforts to broadly motorboat a coronavirus vaccine, particularly arsenic leaders Pfizer and Moderna person already deed the market.

To find the champion stocks to bargain and watch, cheque out IBD Stock Lists. Make definite to besides support tabs connected stocks to bargain oregon sell.

Follow Allison Gatlin connected Twitter astatine @IBD_AGatlin.


Are These Medical Stocks Cruising Toward Big Gains? Here's A Bullish Sign

Why It Might Be Time To Pay Attention To These 4 Red-Hot Health Stocks

Short-Term Trades Can Add Up To Big Profits. IBD's SwingTrader Shows You How

Stock Market Today: Track Market Trends And The Best Stocks To Watch

IBD Long-Term Leaders List

Read Entire Article